UA
CAS 1143-70-0
Purity≥99.0%
Urolithin A material for mitochondrial and healthy-aging research
Urolithin A powder (CAS 1143-70-0) is supplied at ≥99.0% purity for ingredient and dosage-form development. The batch COA documents chemical quality; particle-size and dispersion properties are separate formulation criteria. Evaluation samples are available, with a 100 g MOQ and 100 g, 500 g or 1 kg packs. healthy-aging ingredients
Quote / sample & delivery
Key Specifications
| Product Positioning | Urolithin A material for mitochondrial and healthy-aging research |
| Application Scenarios | mitochondrial research · healthy-aging nutrition formulas · solid-dose screening |
| CAS Number | 1143-70-0 |
| Purity | ≥99.0% |
| Molecular Formula | C₁₃H₈O₄ |
| Molecular Weight | 228.20 g/mol |
| Appearance | Light yellow to yellow powder |
| Solubility | Slightly soluble in water; soluble in DMSO |
| Storage | Room temperature, protect from light |
| Shelf Life | 24 months |
Procurement & delivery
Supply details confirmed by intended use, volume and target market
Urolithin A (UA, CAS 1143-70-0) is a dibenzo-alpha-pyranone studied in mitochondrial and healthy-aging research. This page covers the identified UA powder, rather than a pomegranate extract or an unspecified ellagic-acid ingredient. For supplier evaluation, request the offered lot COA, identity method, purity and assay reporting bases, and source/process documentation. For formulation work, specify particle size, dispersion conditions and the intended dosage form; a raw-material COA alone does not establish performance in a finished product.
Urolithin A Bulk Supply
PathGene supplies Urolithin A, CAS 1143-70-0, with specification ≥99.0%.
Particle-Size and Dispersion Projects
Bulk Urolithin A for formulation development, with particle-size and dispersion requirements included in your project brief.
Batch Quality Documentation
Batch COA supports the quality evaluation of Urolithin A and the agreed purchasing specification.
Evaluation Samples
Request Urolithin A samples for incoming-quality evaluation and project trials.
Supply and Packaging
MOQ: 100 g. Packaging options: 100 g, 500 g, 1 kg.
Test items, specifications and results for the listed batch are shown here. View or request a COA in the quality documents section.
Batch No.
PGUA-260112
Test date
2026-01-13
Specification
In-house
Pack size
25 kg/carton
Storage
Room temperature, protect from light
Conclusion
Conforms
| Test Item | Specification | Result |
|---|---|---|
| Appearance | White to yellow powder | Yellow powder |
| Identification | IR spectrum and HPLC retention time conform to reference | Complies |
| Purity | ≥98% | 99.7% |
| Assay (dry basis) | 98.0%–102% | 99.6% |
| Water | ≤3.0% | 0.3% |
| Residue on ignition | ≤0.5% | 0.25% |
| Lead (Pb) | ≤0.5 ppm | Complies |
| Mercury (Hg) | ≤0.5 ppm | Complies |
| Cadmium (Cd) | ≤0.5 ppm | Complies |
| Arsenic (As) | ≤0.5 ppm | Complies |
| Total plate count | ≤1000 CFU/g | Complies |
| Yeast and mold | ≤100 CFU/g | Complies |
| Coliforms | Not detected | Complies |
| Staphylococcus aureus | Not detected | Complies |
| Salmonella | Not detected | Complies |
View an available COA in the quality documents section. Check the document for its product form and batch; request a signed COA for your purchasing or shipment batch separately.
Softgels
Gummies
Stick-pack powders
Protein powders
Skincare creams
Facial serums
Treat aqueous solubility separately from dispersion; uniform suspension in protein powder is not molecular dissolution.
99.7%
Purity
99.6%
Assay (dry basis)
0.3%
Water
PGUA-260112 · Results apply to this lot; interpret purity, assay and water on their respective bases.
Composition candidates, processing sequences and tests support pilot design. Confirm candidate excipients and processes using this material in the actual finished formulation.
Application examples follow the materials, formats and findings actually studied. Combination studies, single-ingredient studies, commercial precedents and development candidates are distinguished.
Poorly water-soluble UA has a studied softgel format, informing dispersion, loading and dosage-form evaluation.
Show research and formulation insights +Hide details −Combination / selection rationale: Poorly water-soluble UA has a studied softgel format, informing dispersion, loading and dosage-form evaluation.
Published evidence / source details: A 2022 trial in 66 adults aged 65–90 used 250-mg UA softgels, totalling 1000 mg/day for four months. Selected endurance measures improved at two months; the primary walking-distance and maximal-ATP endpoints did not significantly improve versus placebo.
Development insights: Compare particle size, wetting and settling in the fill, then assay start/middle/end filling, shell compatibility and retained samples. Hard capsules and tablets require separate flow, disintegration and dissolution evaluation.
Evidence scope: A specified branded formulation was studied; its amount is not general intake advice or evidence of equivalence for this powder.
2022 · Liu et al. · DOI 10.1001/jamanetworkopen.2021.44279 ↗Protein powder provides a sports-nutrition matrix for separately specified UA; low-level distribution and dispersion are key development questions.
Show research and formulation insights +Hide details −Combination / selection rationale: Protein powder provides a sports-nutrition matrix for separately specified UA; low-level distribution and dispersion are key development questions.
Published evidence / source details: The softgel trial did not evaluate a UA/protein blend and cannot establish added muscular effects from the combination.
Development insights: Premix UA with a carrier fraction before staged protein blending. Compare whey and plant matrices and measure serving assay, settling, reconstitution recovery and flavour; suspension is not molecular dissolution.
Evidence scope: Powder-development candidate requiring finished-blend validation.
2022 · Related UA material/endpoint reference · Liu et al. ↗Literature-Supported Research Directions
Urolithin A is a gut-microbiota-derived postbiotic studied as a mitophagy activator. In a first-in-human study, repeated intake modulated plasma acylcarnitines and skeletal-muscle mitochondrial gene expression in older adults.
Citation: Andreux et al., Nature Metabolism (2019): first-in-human urolithin A trial.View source
Randomized trials in middle-aged and older adults reported changes in muscle endurance and mitochondrial-related biomarkers, while some primary endpoints such as maximal ATP production were not significantly different. These findings support formulation and exercise-nutrition research.
Citation: Liu et al., JAMA Network Open (2022): randomized clinical trial in older adults.View source
Note: For ingredient R&D and scientific information; findings depend on model, dose, formulation and population and do not constitute a treatment claim or efficacy guarantee.
Lead Time
3–5business days
Standard products are generally in stock; confirm the exact lead time with us.
Minimum Order
100 g
Samples, pilot trials, and commercial volumes are supported.
Foil Pouch
Sealed, moisture-protective inner packaging
Fiber Drum
Standard outer packaging for bulk transport
Bulk Shipping
Palletized and stretch-wrapped for protection
Ambient storage: foil pouch + fiber drum; temperature controlled: foil pouch + insulated box/carton. Confirm by product.
Custom packaging: Custom foil bags or HDPE drums, GMP label printing, and export documentation are available. Contact us for a quote.Images are packaging illustrations.
Certifications
Precursor Sourcing & Incoming QC
Hydroxylated aromatic starting materials (a bromo-hydroxybenzoic acid derivative and resorcinol) are sourced and verified by identity and purity testing before release to production.
Copper-Catalyzed Aryl Coupling
The aromatic building blocks undergo a copper-catalyzed coupling reaction under basic (aqueous sodium hydroxide) conditions to form the biaryl intermediate.
Base-Mediated Cyclization / Lactonization
The biaryl intermediate is cyclized under controlled temperature and pH to close the lactone ring and build the characteristic dibenzo-alpha-pyranone (benzo-coumarin) core of urolithin A.
Acidification & Crude Isolation
The resulting sodium salt is protonated by controlled acidification, precipitating crude urolithin A, which is filtered and washed to remove residual inorganic salts.
Purification by Recrystallization
Crude material is purified by recrystallization/trituration (e.g., in an acetic acid-based solvent system) to remove regioisomeric byproducts and trace catalyst residues.
Drying, Milling & Particle Size Control
The purified solid is dried under vacuum, then milled and sieved to achieve a uniform, free-flowing powder within target particle-size specifications.
Final Release Testing & Packaging
Each batch undergoes HPLC assay, identification, heavy metal, and microbial testing before being packaged under moisture-protected, light-controlled conditions for shipment.
Purity is determined by reversed-phase HPLC with UV detection, comparing the sample against a certified urolithin A reference standard under a validated method (typical detection around 254-360 nm). Because urolithin A has structurally similar regioisomers and synthesis-related byproducts, buyers should request the batch-specific HPLC chromatogram, the reference standard used, and the full certificate of analysis, and are encouraged to confirm results with independent third-party testing before large-scale procurement.
Urolithin A is slightly soluble in water but readily dissolves in DMSO and other polar organic solvents such as ethanol or methanol, which is convenient for in vitro research use but limits direct aqueous formulation. For supplement and functional-food applications, common approaches to improve dispersibility and bioavailability include particle-size reduction (micronization), complexation with cyclodextrins, solid dispersion technologies, and lipid-based or self-emulsifying delivery systems. DMSO stock solutions are appropriate for cell-based assays but are not suitable for oral products; formulators should select solvents and excipients compatible with their intended delivery format and regulatory requirements.
Review Urolithin A identity, purity, dry-basis assay and contaminant testing as separate fields, together with their methods. PGUA-260112 is a reference lot record. Purchase acceptance uses the COA matching the actual shipment lot.
No. Because natural conversion of ellagitannins to urolithin A by gut bacteria varies greatly between individuals and yields are low, our material is produced through a controlled multi-step organic synthesis, which gives consistent identity, purity, and supply reliability suitable for commercial use.
It is slightly soluble in water and soluble in DMSO. For water-based or oral formulations, techniques such as micronization, cyclodextrin complexation, or lipid-based delivery systems are commonly used to improve dispersibility; DMSO is best reserved for research/cell-based work.
Yes, small research or evaluation samples are available on request so you can independently verify appearance, solubility, and purity before committing to a bulk order.
Yes. In addition to our internal CoA, we welcome buyers to send samples to an independent laboratory of their choice for third-party verification of purity, heavy metals, and microbial limits.
Yes, we support OEM/private-label packaging, custom specifications, and formulation guidance for customers developing supplement or functional-food finished products.
Urolithin A powder has a 100 g MOQ, with 100 g, 500 g and 1 kg pack options. Standard powder, specified particle sizes and dispersion systems are distinct purchasing requirements. Compare quotations on the same purity, assay basis and required powder properties.
Identity is confirmed by comparing HPLC retention time and UV spectral profile against a reference standard; buyers requiring additional confirmation (e.g., IR or mass spectrometry) can request this be arranged for a specific batch.
No. Define the required mesh or particle-size distribution and the intended dispersion or delivery system separately. Confirm which grade is available and evaluate the sample in the target formula. Do not treat standard powder as a validated micronized, liposomal or encapsulated grade without supporting documents.
Agree the product identity and release specification first, then define any required particle-size method, dispersion assessment and process checks. Compare samples using the same mixing or processing conditions and retain the batch number. A purity result alone does not establish particle size, flow, compression performance or a validated delivery system. Confirm availability before specifying a particular powder grade.
Urolithin A has low aqueous solubility, so distinguish dissolution from dispersion. In softgels, test particle size, wetting, settling, filling uniformity and shell compatibility. In protein powders, measure serving distribution, reconstitution recovery and sediment. A study of a specified UA softgel does not validate a protein blend or every delivery system.
Documents are subject to product and batch availability; third-party reports are provided only when applicable.
Quality documents
The specification sheet defines acceptance limits. The COA shows actual batch results, which may vary by batch. Third-party reports are provided only for products or batches that have been independently tested.
Stable acceptance criteria · Available on request
Actual test data · Check the COA for the applicable batch
Technical Resources
Related Products
Spermidine Trihydrochloride Powder
Pyrroloquinoline Quinone Disodium Salt Powder
Interested in UA?
Our R&D team will respond to your inquiry or sample request within 24 hours.
Scan to add WeChat
Alex Huang · Mon–Fri 9am–6pm CST
